Polymyositis and dermatomyositis – challenges in diagnosis and management

Bohan, 1975, Polymyositis and dermatomyositis (first of two parts), N. Engl. J. Med., 292, 344, 10.1056/NEJM197502132920706 Hoogendijk, 2004, 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands, Neuromuscul. Disord., 14, 337, 10.1016/j.nmd.2004.02.006 Dalakas, 2003, Polymyositis and dermatomyositis, Lancet, 362, 971, 10.1016/S0140-6736(03)14368-1 Castro, 2012, Diagnosis and treatment of inflammatory myopathy: issues and management, Ther Adv Musculoskelet Dis, 4, 111, 10.1177/1759720X11425092 Dalakas, 2015, Inflammatory muscle diseases, N. Engl. J. Med., 372, 1734, 10.1056/NEJMra1402225 Dalakas, 2011, Review: an update on inflammatory and autoimmune myopathies, Neuropathol. Appl. Neurobiol., 37, 226, 10.1111/j.1365-2990.2010.01153.x Jakubaszek, 2015, Polymyositis and dermatomyositis as a risk of developing cancer, Reumatologia, 53, 101, 10.5114/reum.2015.51510 Ceribelli, 2017, The immune response and the pathogenesis of idiopathic inflammatory myositis: a critical review, Clin. Rev. Allergy Immunol., 52, 58, 10.1007/s12016-016-8527-x Shamim, 2000, Familial autoimmunity and the idiopathic inflammatory myopathies, Curr. Rheumatol. Rep., 2, 201, 10.1007/s11926-000-0080-0 Wedgwood, 1953, Dermatomyositis; report of 26 cases in children with a discussion of endocrine therapy in 13, Pediatrics, 12, 447, 10.1542/peds.12.4.447 CHRISTIANSON, 1956, Dermatomyositis: unusual features, complications, and treatment, JAMA Dermatol., 74, 581 Rothwell, 2013, Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies, Curr. Opin. Rheumatol., 25, 735, 10.1097/01.bor.0000434676.70268.66 Rothwell, 2016, New developments in genetics of myositis, Curr. Opin. Rheumatol., 28, 651, 10.1097/BOR.0000000000000328 Chinoy, 2011, Recent advances in the immunogenetics of idiopathic inflammatory myopathy, Arthritis Res. Ther., 13, 216, 10.1186/ar3327 Chinoy, 2009, An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond, Curr. Opin. Rheumatol., 21, 588, 10.1097/BOR.0b013e3283315a22 Miller, 2015, Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes, Genes Immun., 16, 470, 10.1038/gene.2015.28 Rothwell, 2016, Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups, Ann. Rheum. Dis., 75, 1558, 10.1136/annrheumdis-2015-208119 O’Hanlon, 2006, HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies, Arthritis Rheum., 54, 3670, 10.1002/art.22205 Arnett, 1996, Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis, Arthritis Rheum., 39, 1507, 10.1002/art.1780390910 O’Hanlon, 2005, Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 Allelic Profiles and Motifs Define Clinicopathologic Groups in Caucasians, Med., vol. 84, 338, 10.1097/01.md.0000189818.63141.8c Rider, 1999, Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci, Arthritis Rheum., 42, 1285, 10.1002/1529-0131(199906)42:6<1285::AID-ANR28>3.0.CO;2-1 Werth, 2002, Associations of tumor necrosis factor α and HLA polymorphisms with adult dermatomyositis: implications for a unique Pathogenesi1, J. Investig. Dermatol., 119, 617, 10.1046/j.1523-1747.2002.01869.x Chinoy, 2007, Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies, Rheumatology, 46, 1411, 10.1093/rheumatology/kem145 Chinoy, 2012, Genetic association study of NF-kappaB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy, Rheumatology, 51, 794, 10.1093/rheumatology/ker379 Sandoval-Garcia, 2012, The ACTN3 R577X polymorphism is associated with inflammatory myopathies in a Mexican population, Scand. J. Rheumatol., 41, 396, 10.3109/03009742.2012.669495 Sugiura, 2014, Association between a C8orf13-BLK polymorphism and polymyositis/dermatomyositis in the Japanese population: an additive effect with STAT4 on disease susceptibility, PLoS One, 9, 10.1371/journal.pone.0090019 Sugiura, 2012, Positive association between <em>STAT4</em> polymorphisms and polymyositis/dermatomyositis in a Japanese population, Ann. Rheum. Dis., 71, 1646, 10.1136/annrheumdis-2011-200839 Chen, 2014, Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis/dermatomyositis in Chinese Han population, PLoS One, 9, 10.1371/journal.pone.0110044 Wang, 2016, Positive association of genetic variations in the phospholipase C-like 1 gene with dermatomyositis in Chinese Han, Immunol. Res., 64, 204, 10.1007/s12026-015-8738-x Chinoy, 2007, Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK, Ann. Rheum. Dis., 66, 970, 10.1136/ard.2006.068858 Gono, 2010, Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis, Mod. Rheumatol., 20, 466, 10.3109/s10165-010-0311-9 Generali, 2017, Lessons learned from twins in autoimmune and chronic inflammatory diseases, J. Autoimmun., 83, 51, 10.1016/j.jaut.2017.04.005 Rosser, 2016, A clinical update on the significance of the gut microbiota in systemic autoimmunity, J. Autoimmun., 74, 85, 10.1016/j.jaut.2016.06.009 Nagaraju, 2002, Animal models of myositis, Rheum. Dis. Clin. N. Am., 28, 917, 10.1016/S0889-857X(02)00026-1 Mamyrova, 2017, Environmental factors associated with disease flare in juvenile and adult dermatomyositis, Rheumatology, 56, 1342, 10.1093/rheumatology/kex162 Okada, 2003, Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease, Arthritis Rheum., 48, 2285, 10.1002/art.11090 Love, 2009, Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women, Arthritis Rheum., 60, 2499, 10.1002/art.24702 Shah, 2013, Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis, Arthritis Rheum., 65, 1934, 10.1002/art.37985 Marie, 2005, Opportunistic infections in polymyositis and dermatomyositis, Arthritis Rheum., 53, 155, 10.1002/art.21083 Bowles, 1987, Dermatomyositis, polymyositis, and Coxsackie-B-virus infection, Lancet, 1, 1004, 10.1016/S0140-6736(87)92271-9 Carroll, 2011, Dermatomyositis and HIV infection: case report and review of the literature, Rheumatol. Int., 31, 673, 10.1007/s00296-009-1231-x Fang, 2016, Malignancy in dermatomyositis and polymyositis: analysis of 192 patients, Clin. Rheumatol., 35, 1977, 10.1007/s10067-016-3296-8 Yang, 2014, Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma, Korean J. Intern. Med., 29, 231, 10.3904/kjim.2014.29.2.231 Chou, 2017, Dermatomyositis induced by hepatitis B virus-related hepatocellular carcinoma: a case report and review of the literature, Intern. Med., 56, 1831, 10.2169/internalmedicine.56.7595 Schiffenbauer, 2018, The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis, Semin. Arthritis Rheum., 48, 504, 10.1016/j.semarthrit.2018.02.003 Evans, 2017, Beyond the MHC: a canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci, PLoS Genet., 13, 10.1371/journal.pgen.1006604 Katsumata, 2008, Animal models in myositis, Curr. Opin. Rheumatol., 20, 681, 10.1097/BOR.0b013e328310e0ac Rosenberg, 1993, Experimental models of inflammatory myopathies, Bailliere. Clin. Neurol., 2, 693 Weller, 1997, Spontaneous myopathy in the SJL/J mouse: pathology and strength loss, Muscle Nerve, 20, 72, 10.1002/(SICI)1097-4598(199701)20:1<72::AID-MUS10>3.0.CO;2-3 Rosenberg, 1987, Experimental autoimmune myositis in SJL/J mice, Clin. Exp. Immunol., 68, 117 Dalakas, 2006, Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies, Nat. Clin. Pract. Rheumatol., 2, 219, 10.1038/ncprheum0140 Dalakas, 2011, Pathophysiology of inflammatory and autoimmune myopathies, Presse Med., 40, e237, 10.1016/j.lpm.2011.01.005 Dalakas, 2010, Immunotherapy of myositis: issues, concerns and future prospects, Nat. Rev. Rheumatol., 6, 129, 10.1038/nrrheum.2010.2 Schmidt, 2010, Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies, Expert Opin. Med. Diagn., 4, 241, 10.1517/17530051003713499 Wiendl, 2005, Immunobiology of muscle: advances in understanding an immunological microenvironment, Trends Immunol., 26, 373, 10.1016/j.it.2005.05.003 Bender, 1995, T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells, J. Exp. Med., 181, 1863, 10.1084/jem.181.5.1863 Hofbauer, 2003, Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis, Proc. Natl. Acad. Sci. U. S. A., 100, 4090, 10.1073/pnas.0236183100 Schmidt, 2004, Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity, Brain, 127, 1182, 10.1093/brain/awh148 De Paepe, 2009, Role of cytokines and chemokines in idiopathic inflammatory myopathies, Curr. Opin. Rheumatol., 21, 610, 10.1097/BOR.0b013e3283317b31 Wiendl, 2003, Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies, Brain, 126, 1026, 10.1093/brain/awg114 Goebels, 1996, Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis, J. Clin. Investig., 97, 2905, 10.1172/JCI118749 Kissel, 1986, Microvascular deposition of complement membrane attack complex in dermatomyositis, N. Engl. J. Med., 314, 329, 10.1056/NEJM198602063140601 Emslie-Smith, 1990, Microvascular changes in early and advanced dermatomyositis: a quantitative study, Ann. Neurol., 27, 343, 10.1002/ana.410270402 Pestronk, 2011, Acquired immune and inflammatory myopathies: pathologic classification, Curr. Opin. Rheumatol., 23, 595, 10.1097/BOR.0b013e32834bab42 Lahoria, 2016, Microvascular alterations and the role of complement in dermatomyositis, Brain, 139, 1891, 10.1093/brain/aww122 Fasth, 2009, T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells, J. Immunol., 183, 4792, 10.4049/jimmunol.0803688 Pandya, 2016, Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis, Arthritis Res. Ther., 18, 80, 10.1186/s13075-016-0974-5 Hohlfeld, 1991, Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies, Ann. Neurol., 29, 498, 10.1002/ana.410290509 Shimojima, 2017, T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis, Autoimmunity, 50, 481, 10.1080/08916934.2017.1405942 Nishio, 2001, Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis, J. Immunol., 167, 4051, 10.4049/jimmunol.167.7.4051 Benveniste, 2001, Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients, J. Immunol., 167, 3521, 10.4049/jimmunol.167.6.3521 O’Hanlon, 1994, Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies, J. Immunol., 152, 2569, 10.4049/jimmunol.152.5.2569 Waschbisch, 2010, FOXP3+ T regulatory cells in idiopathic inflammatory myopathies, J. Neuroimmunol., 225, 137, 10.1016/j.jneuroim.2010.03.013 Vercoulen, 2014, Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood, PLoS One, 9, 10.1371/journal.pone.0105353 Greenberg, 2005, Plasma cells in muscle in inclusion body myositis and polymyositis, Neurology, 65, 1782, 10.1212/01.wnl.0000187124.92826.20 Wang, 2012, Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis, Clin. Rheumatol., 31, 1691, 10.1007/s10067-012-2075-4 Kryštůfková, 2009, Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies, Ann. Rheum. Dis., 68, 836, 10.1136/ard.2008.091405 Baek, 2012, The expression of BAFF in the muscles of patients with dermatomyositis, J. Neuroimmunol., 249, 96, 10.1016/j.jneuroim.2012.04.006 Peng, 2014, B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis, Biomark. Med., 8, 395, 10.2217/bmm.13.124 Kryštůfková, 2014, Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies, Arthritis Res. Ther., 16, 454, 10.1186/s13075-014-0454-8 Tournadre, 2010, Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines, Arthritis Rheum., 62, 2144 Brunn, 2012, Toll-like receptors promote inflammation in idiopathic inflammatory myopathies, J. Neuropathol. Exp. Neurol., 71, 855, 10.1097/NEN.0b013e31826bf7f3 Kikuchi, 2001, Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells, Ann. Rheum. Dis., 60, 1137, 10.1136/ard.60.12.1137 Bradshaw, 2007, A local antigen-driven humoral response is present in the inflammatory myopathies, J. Immunol., 178, 547, 10.4049/jimmunol.178.1.547 McIntyre, 2014, The V(H) repertoire and clonal diversification of B cells in inflammatory myopathies, Eur. J. Immunol., 44, 585, 10.1002/eji.201343315 Valiyil, 2010, Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series, Arthritis Care Res., 62, 1328, 10.1002/acr.20219 Hornung, 2014, Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment, Drugs, 74, 981, 10.1007/s40265-014-0240-6 Wenzel, 2006, Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis, Clin. Exp. Dermatol., 31, 576, 10.1111/j.1365-2230.2006.02150.x Wenzel, 2005, Evidence for a role of type I interferons in the pathogenesis of dermatomyositis, Br. J. Dermatol., 153, 462, 10.1111/j.1365-2133.2005.06786.x Walsh, 2007, Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis, Arthritis Rheum., 56, 3784, 10.1002/art.22928 Greenberg, 2005, Interferon-α/β–mediated innate immune mechanisms in dermatomyositis, Ann. Neurol., 57, 664, 10.1002/ana.20464 Page, 2004, Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells, Arthritis Rheum., 50, 199, 10.1002/art.11428 Yokota, 2014, Roles of mast cells in the pathogenesis of inflammatory myopathy, Arthritis Res. Ther., 16, R72, 10.1186/ar4512 Zhang, 2014, Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications, Clin. Exp. Immunol., 177, 134, 10.1111/cei.12319 Rostasy, 2004, Monocyte/macrophage differentiation in dermatomyositis and polymyositis, Muscle Nerve, 30, 225, 10.1002/mus.20088 Shimizu, 2014, Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis, Rheumatology, 53, 766, 10.1093/rheumatology/ket360 Peng, 2015, Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue, J. Rheumatol., 42, 979, 10.3899/jrheum.141307 Ascherman, 2002, Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis, J. Immunol., 169, 7127, 10.4049/jimmunol.169.12.7127 Karpati, 1988, Expression of immunoreactive major histocompatibility complex products in human skeletal muscles, Ann. Neurol., 23, 64, 10.1002/ana.410230111 Sugiura, 2000, Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production, J. Immunol., 164, 6593, 10.4049/jimmunol.164.12.6593 Xiaoyu, 2011, Expression of B7-homolog 1 in polymyositis, Ann. Clin. Lab. Sci., 41, 154 Uruha, 2017, Sarcoplasmic MxA expression: a valuable marker of dermatomyositis, Neurology, 88, 493, 10.1212/WNL.0000000000003568 Behrens, 1997, Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells, Brain, 120, 929, 10.1093/brain/120.6.929 Schneider, 1996, MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis, J. Neuropathol. Exp. Neurol., 55, 1205, 10.1097/00005072-199612000-00003 Nagaraju, 2000, The inhibition of apoptosis in myositis and in normal muscle cells, J. Immunol., 164, 5459, 10.4049/jimmunol.164.10.5459 Li, 2000, Expression of human IAP-like protein in skeletal muscle: a possible explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies, J. Neuroimmunol., 106, 1, 10.1016/S0165-5728(99)00162-9 Dalakas, 1991, Polymyositis, dermatomyositis and inclusion-body myositis, N. Engl. J. Med., 325, 1487, 10.1056/NEJM199111213252107 Griggs, 1995, Inclusion body myositis and myopathies, Ann. Neurol., 38, 705, 10.1002/ana.410380504 Finsterer, 2010, Steroid-responsive dropped-head-syndrome due to polymyositis, Jt. Bone Spine, 77, 485, 10.1016/j.jbspin.2010.02.028 Ebert, 2010, Review article: the gastrointestinal complications of myositis, Aliment. Pharmacol. Ther., 31, 359, 10.1111/j.1365-2036.2009.04190.x de Merieux, 1983, Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis, Arthritis Rheum., 26, 961, 10.1002/art.1780260804 Greenberg, 2008, Inflammatory myopathies: evaluation and management, Semin. Neurol., 28, 241, 10.1055/s-2008-1062267 Mozaffar, 2000, Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres, J. Neurol. Neurosurg. Psychiatry, 68, 472, 10.1136/jnnp.68.4.472 Mammen, 2011, Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis, Nat. Rev. Neurol., 7, 343, 10.1038/nrneurol.2011.63 Katzap, 2011, Antisynthetase syndrome, Curr. Rheumatol. Rep., 13, 175, 10.1007/s11926-011-0176-8 Amato, 2009, Evaluation and treatment of inflammatory myopathies, J. Neurol. Neurosurg. Psychiatry, 80, 1060, 10.1136/jnnp.2008.169375 Chahin, 2008, Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM, Neurology, 70, 418, 10.1212/01.wnl.0000277527.69388.fe Amato, 2003, Unicorns, dragons, polymyositis, and other mythological beasts, Neurology, 61, 288, 10.1212/WNL.61.3.288 Shi, 2019, A case of Kennedy’s disease misdiagnosed as polymyositis, Scand. J. Rheumatol., 48, 168, 10.1080/03009742.2018.1488989 Gherardi, 1998, Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Francaise contre les Myopathies (AFM), Lancet, 352, 347, 10.1016/S0140-6736(98)02326-5 Hertzman, 1990, Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan, N. Engl. J. Med., 322, 869, 10.1056/NEJM199003293221301 van der Meulen, 2003, Polymyositis: an overdiagnosed entity, Neurology, 61, 316, 10.1212/WNL.61.3.316 Doyle, 1983, Fatal polymyositis in D-penicillamine-treated rheumatoid arthritis, Ann. Intern. Med., 98, 327, 10.7326/0003-4819-98-3-327 Dalakas, 1990, Mitochondrial myopathy caused by long-term zidovudine therapy, N. Engl. J. Med., 322, 1098, 10.1056/NEJM199004193221602 Iaccarino, 2014, The clinical features, diagnosis and classification of dermatomyositis, J. Autoimmun., 48–49, 122, 10.1016/j.jaut.2013.11.005 Bailey, 2014, Amyopathic dermatomyositis: definitions, diagnosis, and management, Curr. Rheumatol. Rep., 16, 465, 10.1007/s11926-014-0465-0 Findlay, 2015, An overview of polymyositis and dermatomyositis, Muscle Nerve, 51, 638, 10.1002/mus.24566 Ramanan, 2002, Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes, Rheum. Dis. Clin. N. Am., 28, 833, 10.1016/S0889-857X(02)00024-8 McCann, 2006, The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr, Rheumatology, 45, 1255, 10.1093/rheumatology/kel099 Compeyrot-Lacassagne, 2005, Inflammatory myopathies in children, Pediatr. Clin. N. Am., 52, 493, 10.1016/j.pcl.2005.01.004 Ramanan, 2002, Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes, Rheum. Dis. Clin. N. Am., 28, 833, 10.1016/S0889-857X(02)00024-8 Khan, 2011, Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features, Rheum. Dis. Clin. N. Am., 37, 143, 10.1016/j.rdc.2011.01.001 Targoff, 2006, A novel autoantibody to a 155-kd protein is associated with dermatomyositis, Arthritis Rheum., 54, 3682, 10.1002/art.22164 Bingham, 2008, Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity, Medicine (Baltim.), 87, 70, 10.1097/MD.0b013e31816bc604 Gunawardena, 2008, Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis, Rheumatology, 47, 324, 10.1093/rheumatology/kem359 Tansley, 2013, Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?, Arthritis Res. Ther., 15, 211, 10.1186/ar4198 Danko, 2004, Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases, Medicine (Baltim.), 83, 35, 10.1097/01.md.0000109755.65914.5e Schwartz, 2016, Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies, RMD Open, 2, 10.1136/rmdopen-2016-000291 Gupta, 2011, Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review, Int. J. Cardiol., 148, 261, 10.1016/j.ijcard.2010.08.013 Diederichsen, 2017, Cardiovascular involvement in myositis, Curr. Opin. Rheumatol., 29, 598, 10.1097/BOR.0000000000000442 Zhang, 2012, Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review, Clin. Cardiol., 35, 686 Rai, 2016, Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study, Rheumatology, 55, 461 Rosenbohm, 2015, Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography, J. Neurol., 262, 949 Chen, 2018, Diagnostic approach to cardiac involvement in idiopathic inflammatory myopathies, Int. Heart J., 59, 256, 10.1536/ihj.17-204 Hughes, 2015, Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity, Ann. Rheum. Dis., 74, 795, 10.1136/annrheumdis-2014-206812 Albayda, 2018, Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement, Semin. Arthritis Rheum., 47, 552, 10.1016/j.semarthrit.2017.06.004 Mavrogeni, 2013, Myocarditis during acute inflammatory myopathies: evaluation using clinical criteria and cardiac magnetic resonance imaging, Int. J. Cardiol., 164, e3, 10.1016/j.ijcard.2012.09.109 Allanore, 2006, Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging, Ann. Rheum. Dis., 65, 249, 10.1136/ard.2005.038679 Ye, 2007, Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study, Clin. Rheumatol., 26, 1647, 10.1007/s10067-007-0562-9 Won Huh, 2007, Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis, Respir. Med., 101, 1761, 10.1016/j.rmed.2007.02.017 Hayashi, 2008, High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis, J. Rheumatol., 35, 260 Fujisawa, 2005, Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis, J. Rheumatol., 32, 58 Saketkoo, 2014, Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases, J. Rheumatol., 41, 792, 10.3899/jrheum.131251 Marie, 2002, Interstitial lung disease in polymyositis and dermatomyositis, Arthritis Rheum., 47, 614, 10.1002/art.10794 Fujisawa, 2014, Prognostic factors for myositis-associated interstitial lung disease, PLoS One, 9, 10.1371/journal.pone.0098824 Chen, 2009, Interstitial lung disease in polymyositis and dermatomyositis, Clin. Rheumatol., 28, 639, 10.1007/s10067-009-1110-6 Mimori, 2012, Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment, Curr. Rheumatol. Rep., 14, 264, 10.1007/s11926-012-0246-6 Chua, 2012, Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort, Rheumatology, 51, 1870, 10.1093/rheumatology/kes167 Lee, 2002, Idiopathic inflammatory myopathy with diffuse alveolar damage, Clin. Rheumatol., 21, 391, 10.1007/s100670200104 Gono, 2012, Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population, Arthritis Rheum., 64, 3736, 10.1002/art.34657 Bauhammer, 2016, Rituximab in the treatment of Jo1 antibody–associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response, J. Rheumatol., 43, 1566, 10.3899/jrheum.150844 Betteridge, 2016, Myositis-specific autoantibodies: an important tool to support diagnosis of myositis, J. Intern. Med., 280, 8, 10.1111/joim.12451 Buchbinder, 2001, Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study, Ann. Intern. Med., 134, 1087, 10.7326/0003-4819-134-12-200106190-00008 Hill, 2001, Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, Lancet, 357, 96, 10.1016/S0140-6736(00)03540-6 Lee, 2006, Malignancies in Korean patients with inflammatory myopathy, Yonsei Med. J., 47, 519, 10.3349/ymj.2006.47.4.519 Fung, 1998, Amyopathic dermatomyositis in Hong Kong -- association with nasopharyngeal carcinoma, Int. J. Dermatol., 37, 659, 10.1046/j.1365-4362.1998.00453.x Chen, 2001, Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study, Br. J. Dermatol., 144, 825, 10.1046/j.1365-2133.2001.04140.x Marie, 2012, Hematological malignancy associated with polymyositis and dermatomyositis, Autoimmun. Rev., 11, 615, 10.1016/j.autrev.2011.10.024 Huang, 2009, Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study, Br. J. Dermatol., 161, 854, 10.1111/j.1365-2133.2009.09274.x Marie, 1999, Influence of age on characteristics of polymyositis and dermatomyositis in adults, Medicine (Baltim.), 78, 139, 10.1097/00005792-199905000-00001 Amoura, 2005, Tumor antigen markers for the detection of solid cancers in inflammatory myopathies, Cancer Epidemiol. Biomark. Prev., 14, 1279, 10.1158/1055-9965.EPI-04-0624 Albert, 2004, Paraneoplastic neurological degenerations: keys to tumour immunity, Nat. Rev. Cancer, 4, 36, 10.1038/nrc1255 Ponyi, 2005, Cancer-associated myositis: clinical features and prognostic signs, Ann. N. Y. Acad. Sci., 1051, 64, 10.1196/annals.1361.047 Levine, 2006, Cancer and myositis: new insights into an old association, Curr. Opin. Rheumatol., 18, 620, 10.1097/01.bor.0000245721.02512.77 Hida, 2016, Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study, Neurology, 87, 299, 10.1212/WNL.0000000000002863 Yang, 2017, Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study, Arthritis Res. Ther., 19, 259, 10.1186/s13075-017-1469-8 Chinoy, 2007, The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis, Ann. Rheum. Dis., 66, 1345, 10.1136/ard.2006.068502 Noda, 2016, Gene expression profile of inflammatory myopathy with malignancy is similar to that of dermatomyositis rather than polymyositis, Intern. Med., 55, 2571, 10.2169/internalmedicine.55.6706 Danielsson, 2017, Increased prevalence of celiac disease in idiopathic inflammatory myopathies, Brain Behav., 7, 10.1002/brb3.803 Selva-O’Callaghan, 2007, Celiac disease and antibodies associated with celiac disease in patients with inflammatory myopathy, Muscle Nerve, 35, 49, 10.1002/mus.20652 Yen, 2005, Renal involvement in patients with polymyositis and dermatomyositis, Int. J. Clin. Pract., 59, 188, 10.1111/j.1742-1241.2004.00248.x Couvrat-Desvergnes, 2014, The spectrum of renal involvement in patients with inflammatory myopathies, Medicine (Baltim.), 93, 33, 10.1097/MD.0000000000000015 Cucchiari, 2017, Renal involvement in idiopathic inflammatory myopathies, Clin. Rev. Allergy Immunol., 52, 99, 10.1007/s12016-015-8524-5 Clements, 1978, Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations, Arthritis Rheum., 21, 62, 10.1002/art.1780210111 Sharp, 1972, Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA), Am. J. Med., 52, 148, 10.1016/0002-9343(72)90064-2 Meneghel, 2017, Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis, Rheumatology, 56, 1822, 10.1093/rheumatology/kex262 Quecedo, 1996, Partial lipodystrophy associated with juvenile dermatomyositis: report of two cases, Pediatr. Dermatol., 13, 477, 10.1111/j.1525-1470.1996.tb00728.x Huemer, 2001, Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities, J. Rheumatol., 28, 610 Schiopu, 2012, Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine, Arthritis Res. Ther., 14, R22, 10.1186/ar3704 Tollisen, 2012, Quality of life in adults with juvenile-onset dermatomyositis: a case-control study, Arthritis Care Res., 64, 1020 Mathiesen, 2013, Aerobic fitness after JDM--a long-term follow-up study, Rheumatology, 52, 287, 10.1093/rheumatology/kes232 Bohan, 1975, Polymyositis and dermatomyositis (second of two parts), N. Engl. J. Med., 292, 403, 10.1056/NEJM197502202920807 Milisenda, 2014, The diagnosis and classification of polymyositis, J. Autoimmun., 48–49, 118, 10.1016/j.jaut.2014.01.025 Miller, 2001, Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheumatology, 40, 1262, 10.1093/rheumatology/40.11.1262 Rider, 2002, Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies, Rheum. Dis. Clin. N. Am., 28, 935, 10.1016/S0889-857X(02)00027-3 Bohan, 1977, Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis, Medicine (Baltim.), 56, 255, 10.1097/00005792-197707000-00001 Malik, 2016, Idiopathic inflammatory myopathies: clinical approach and management, Front. Neurol., 7, 64, 10.3389/fneur.2016.00064 Yuan, 2013, Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis, Clin. Exp. Rheumatol., 31, 428 Gabay, 1994, Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response, Arthritis Rheum., 37, 1744, 10.1002/art.1780371206 Ghirardello, 2006, Clinical implications of autoantibody screening in patients with autoimmune myositis, Autoimmunity, 39, 217, 10.1080/08916930600622645 Gazeley, 2011, Diagnosis and treatment of the idiopathic inflammatory myopathies, Ther Adv Musculoskelet Dis, 3, 315, 10.1177/1759720X11415306 Ghirardello, 2013, Autoantibodies in polymyositis and dermatomyositis, Curr. Rheumatol. Rep., 15, 335, 10.1007/s11926-013-0335-1 Tomasova Studynkova, 2007, The role of MRI in the assessment of polymyositis and dermatomyositis, Rheumatology, 46, 1174, 10.1093/rheumatology/kem088 Adams, 1995, The idiopathic inflammatory myopathies: spectrum of MR imaging findings, RadioGraphics, 15, 563, 10.1148/radiographics.15.3.7624563 Schulze, 2009, MRI findings in inflammatory muscle diseases and their noninflammatory mimics, AJR Am. J. Roentgenol., 192, 1708, 10.2214/AJR.08.1764 Kimball, 2000, Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy, Arthritis Rheum., 43, 1866, 10.1002/1529-0131(200008)43:8<1866::AID-ANR24>3.0.CO;2-6 Maillard, 2004, Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis, Rheumatology, 43, 603, 10.1093/rheumatology/keh130 Del Grande, 2011, Magnetic Resonance Imaging of Inflammatory Myopathies, 22, 39 Brown, 2006, An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM), Rheumatology, 45, 990, 10.1093/rheumatology/kel025 Adler, 2009, Ultrasound in the evaluation of the inflammatory myopathies, Curr. Rheumatol. Rep., 11, 302, 10.1007/s11926-009-0042-0 Weber, 2009, Ultrasound in the inflammatory myopathies, Ann. N. Y. Acad. Sci., 1154, 159, 10.1111/j.1749-6632.2009.04390.x Arahata, 1984, Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells, Ann. Neurol., 16, 193, 10.1002/ana.410160206 Lazarou, 2013, Classification, diagnosis, and management of idiopathic inflammatory myopathies, J. Rheumatol., 40, 550, 10.3899/jrheum.120682 Luo, 2015, Dermatomyositis, polymyositis and immune-mediated necrotising myopathies, Biochim. Biophys. Acta, 1852, 622, 10.1016/j.bbadis.2014.05.034 Engel, 2006, Inclusion-body myositis: clinical, diagnostic, and pathologic aspects, Neurology, 66, S20, 10.1212/01.wnl.0000192260.33106.bb Dalakas, 2010, Inflammatory muscle diseases: a critical review on pathogenesis and therapies, Curr. Opin. Pharmacol., 10, 346, 10.1016/j.coph.2010.03.001 Dalakas, 2008, Therapeutic advances and future prospects in immune-mediated inflammatory myopathies, Ther. Adv. Neurol. Disord., 1, 157, 10.1177/1756285608097463 Dalakas, 2011, Immunotherapy of inflammatory myopathies: practical approach and future prospects, Curr. Treat. Options Neurol., 13, 311, 10.1007/s11940-011-0119-8 Mastaglia, 2003, Inflammatory myopathies: how to treat the difficult cases, J. Clin. Neurosci., 10, 99, 10.1016/S0967-5868(02)00271-0 van de Vlekkert, 2010, Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial, Neuromuscul. Disord., 20, 382, 10.1016/j.nmd.2010.03.011 Ernste, 2013, Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations, Mayo Clin. Proc., 88, 83, 10.1016/j.mayocp.2012.10.017 Hoffman, 1983, Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital, Am. J. Med., 75, 433, 10.1016/0002-9343(83)90344-3 Joffe, 1993, Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy, Am. J. Med., 94, 379, 10.1016/0002-9343(93)90148-I Drake, 1996, Guidelines of care for dermatomyositis. American academy of dermatology, J. Am. Acad. Dermatol., 34, 824 Troyanov, 2005, Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients, Medicine (Baltim.), 84, 231, 10.1097/01.md.0000173991.74008.b0 Danieli, 2011, Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application, Autoimmun. Rev., 10, 144, 10.1016/j.autrev.2010.09.004 Dalakas, 1993, A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis, N. Engl. J. Med., 329, 1993, 10.1056/NEJM199312303292704 Ramirez, 1990, Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment, Semin. Arthritis Rheum., 20, 114, 10.1016/0049-0172(90)90024-A Hollingworth, 1982, Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases, Ann. Rheum. Dis., 41, 557, 10.1136/ard.41.6.557 Miller, 2002, vol. 199, S53 Bunch, 1981, Prednisone and azathioprine for polymyositis: long-term followup, Arthritis Rheum., 24, 45, 10.1002/art.1780240107 Malaviya, 1968, Treatment of dermatomyositis with methotrexate, Lancet, 2, 485, 10.1016/S0140-6736(68)90649-1 Zieglschmid-Adams, 1998, The value of methotrexate in dermatomyositis, J. Am. Acad. Dermatol., 38, 130, 10.1016/S0190-9622(98)70562-6 Villalba, 1998, Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens, Arthritis Rheum., 41, 392, 10.1002/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X Dalakas, 2011, Inflammatory myopathies: management of steroid resistance, Curr. Opin. Neurol., 24, 457, 10.1097/WCO.0b013e32834a9589 Dalakas, 2008, B cells as therapeutic targets in autoimmune neurological disorders, Nat. Clin. Pract. Neurol., 4, 557, 10.1038/ncpneuro0901 Levine, 2005, Rituximab in the treatment of dermatomyositis: an open-label pilot study, Arthritis Rheum., 52, 601, 10.1002/art.20849 Chung, 2007, A pilot trial of rituximab in the treatment of patients with dermatomyositis, Arch. Dermatol., 143, 763, 10.1001/archderm.143.6.763 Innami, 2017, Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis, BMJ Case Rep., 2017 Aggarwal, 2017, Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab, Rheumatology, 56, 247, 10.1093/rheumatology/kew396 Nalotto, 2013, Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature, Immunol. Res., 56, 362, 10.1007/s12026-013-8408-9 Sem, 2009, Rituximab treatment of the anti-synthetase syndrome: a retrospective case series, Rheumatology, 48, 968, 10.1093/rheumatology/kep157 Aggarwal, 2014, Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis, Arthritis Rheum., 66, 740, 10.1002/art.38270 Hengstman, 2003, Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations, Eur. Neurol., 50, 10, 10.1159/000070852 Schiffenbauer, 2018, A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis, Semin. Arthritis Rheum., 47, 858, 10.1016/j.semarthrit.2017.10.010 Dastmalchi, 2008, A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies, Ann. Rheum. Dis., 67, 1670, 10.1136/ard.2007.077974 2011, A randomized, pilot trial of etanercept in dermatomyositis, Ann. Neurol., 70, 427, 10.1002/ana.22477 Thompson, 2008, Alemtuzumab (Campath-1H) for treatment of refractory polymyositis, J. Rheumatol., 35, 2080 Reiff, 2011, Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis, J. Clin. Immunol., 31, 615, 10.1007/s10875-011-9533-7 Marie, 2011, Therapy of polymyositis and dermatomyositis, Presse Med., 40, e257, 10.1016/j.lpm.2010.12.012 Alexanderson, 2012, Exercise in inflammatory myopathies, including inclusion body myositis, Curr. Rheumatol. Rep., 14, 244, 10.1007/s11926-012-0248-4 Wiesinger, 1998, Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme, Br. J. Rheumatol., 37, 196, 10.1093/rheumatology/37.2.196 Johnson, 2009, Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis, J. Clin. Neuromuscul. Dis., 10, 178, 10.1097/CND.0b013e3181a23c86 Chung, 2007, Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial, Arthritis Rheum., 57, 694, 10.1002/art.22687 Bendewald, 2010, Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota, Arch. Dermatol., 146, 26, 10.1001/archdermatol.2009.328 Rosa, 2013, Incidence and prevalence of polymyositis and dermatomyositis in a, Health Management Organization in Buenos Aires, 19, 303 Vargas-Leguas, 2007, [Polymyositis-dermatomyositis: incidence in Spain (1997-2004)], Med. Clínica, 129, 721, 10.1157/13113285 Ohta, 2014, Prevalence and incidence of polymyositis and dermatomyositis in Japan, Mod. Rheumatol., 24, 477, 10.3109/14397595.2013.844308 Cho, 2019, Incidence and prevalence of idiopathic inflammatory myopathies in korea: a nationwide population-based study, J. Korean Med. Sci., 34 Bernatsky, 2009, Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences, Ann. Rheum. Dis., 68, 1192, 10.1136/ard.2008.093161 Smoyer-Tomic, 2012, Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis, BMC Muscoskelet. Disord., 13, 103, 10.1186/1471-2474-13-103 Furst, 2012, Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan, Muscle Nerve, 45, 676, 10.1002/mus.23302 Kuo, 2011, Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study, Br. J. Dermatol., 165, 1273, 10.1111/j.1365-2133.2011.10595.x Rose, 2013, 188th ENMC international workshop: inclusion body myositis, 2-4 december 2011, naarden, The Netherlands, Neuromuscul. Disord., 23, 1044, 10.1016/j.nmd.2013.08.007 Love, 2009, Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti–Mi-2 autoantibodies in women, Arthritis Rheum., 60, 2499, 10.1002/art.24702 Hamaguchi, 2011, Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional StudyDM-specific autoantibodies in patients with DM, JAMA Dermatol., 147, 391, 10.1001/archdermatol.2011.52 Joffe, 1993, Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy, Am. J. Med., 94, 379, 10.1016/0002-9343(93)90148-I Hoshino, 2010, Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis, Rheumatology, 49, 1726, 10.1093/rheumatology/keq153 Kobayashi, 2011, Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis, J. Pediatr., 158, 675, 10.1016/j.jpeds.2010.11.033 Ge, 2017, Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts, Sci. Rep., 7, 188, 10.1038/s41598-017-00240-6 Chinoy, 2007, The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis, Ann. Rheum. Dis., 66, 1345, 10.1136/ard.2006.068502 Casciola-Rosen, 2012, Myositis autoantibodies, 24, 602 Gunawardena, 2009, Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis, Arthritis Rheum., 60, 1807, 10.1002/art.24547 Christopher-Stine, 2010, A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis Rheum., 62, 2757, 10.1002/art.27572 Tansley, 2017, Anti-hmgcr autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients, J. Rheumatol., 44, 488, 10.3899/jrheum.160871 Kao, 2004, Anti–signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy, Arthritis Rheum., 50, 209, 10.1002/art.11484 Targoff, 1997, Classification criteria for the idiopathic inflammatory myopathies, Curr. Opin. Rheumatol., 9, 527, 10.1097/00002281-199711000-00008 Lega, 2014, The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome, Autoimmun. Rev., 13, 883, 10.1016/j.autrev.2014.03.004 Coppo, 2002, Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome, Rheumatology, 41, 1040, 10.1093/rheumatology/41.9.1040 Plestilova, 2013, THU0253ANTI-PM-SCL autoantibodies in polymyositis and dermatomyositis, Ann. Rheum. Dis., 71, 240, 10.1136/annrheumdis-2012-eular.2218 Marie, 2010, Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody, Br. J. Dermatol., 162, 337, 10.1111/j.1365-2133.2009.09484.x Rigolet, 2012, Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease, Medicine (Baltim.), 91, 95, 10.1097/MD.0b013e31824d9cec